Summary: The established impact of gut microbiota-and probiotic-derived metabolites on immune-checkpoint blockade (ICB) has spurred extensive efforts to identify strains and druggable bioactive molecules of microbial origin that can improve tumor immune therapy. In this issue, Kawanabe-Matsuda and colleagues show that the exopolysaccharide EPS-R1 produced by the probiotic strain Lactobacillus delbrueckii subsp. bulgaricus augments the response to ICB therapy by expanding the population of Peyer’s patches CCR6+ CD8+ T cells, which can subsequently migrate from the gut into CCL20-expressing tumors to enhance antitumor activity.

Original languageEnglish
Pages (from-to)1189-1190
Number of pages2
JournalCancer discovery
Issue number5
StatePublished - May 1 2022


Dive into the research topics of 'Precision Probiotic Medicine to Improve ICB Immunotherapy'. Together they form a unique fingerprint.

Cite this